Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed

Rakuten Medical President Takashi Toraishi If all goes well, Rakuten Medical could reach a filing in 2022 for its investigational head and neck cancer therapy ASP-1929 - an antibody drug conjugate (ADC) that works on its unique “photoimmunotherapy” platform -...read more